News | December 14, 2025
Biocon Biologics strikes deal to sell its version of the eye drug Aflibercept worldwide
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Granules Consumer Health serves as Granules’ front-end division for OTC products in the US
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
Renalyx will continue operating as an independent unit within the group
The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years
The device delivers clear, high-quality images to support accurate diagnoses across a broad range of patient groups
RedHill has obtained a court-approved asset attachment in South Korea to prevent Kukbo from transferring or disposing of assets ahead of enforcement of the judgment
The FDA’s review also revealed delays in Philips’ internal investigations, with 54 inquiries failing to meet targeted completion dates—23 of which were delayed by more than 100 days
Subscribe To Our Newsletter & Stay Updated
